• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

    2.410 -0.210 (-8.02%)
    Streaming Delayed Price Updated: 3:52 PM EDT, Mar 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about C4 Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021 ↗
    Upgrades Keefe, Bruyette & Woods upgraded the previous rating for CBRE Group Inc (NYSE: 
    Via Benzinga
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021 ↗
    Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
    Via Benzinga
    News headline image
    C4 Therapeutics Multiple Myeloma Candidate Scores FDA Orphan Drug Tag ↗
    The FDA has granted Orphan Drug Designation to C4 Therapeutics Inc (NASDAQ: CCCC) CFT7455 for multiple myeloma. CFT7455 is an orally bioavailable MonoDAC... 
    Via Benzinga
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021 ↗
    Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
    Via Benzinga
    News headline image
    C4 Therapeutics Stock Enters Leadership Territory ↗
    A Relative Strength Rating upgrade for C4 Therapeutics shows improving technical performance. 
    Via Investor's Business Daily
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For June 4, 2021 ↗
    Upgrades According to Argus Research, the prior rating for Diageo PLC (NYSE:DEO) was changed from Hold to Buy. The current stock performance of Diageo shows a 52-week-high... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.